KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Operating Expenses (2016 - 2025)

Jazz Pharmaceuticals has reported Operating Expenses over the past 16 years, most recently at $943.4 million for Q4 2025.

  • Quarterly Operating Expenses rose 5.12% to $943.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 billion through Dec 2025, up 11.69% year-over-year, with the annual reading at $4.7 billion for FY2025, 40.14% up from the prior year.
  • Operating Expenses was $943.4 million for Q4 2025 at Jazz Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • Over five years, Operating Expenses peaked at $1.7 billion in Q2 2025 and troughed at $445.5 million in Q1 2021.
  • The 5-year median for Operating Expenses is $835.8 million (2024), against an average of $894.8 million.
  • Peak annual rise in Operating Expenses hit 125.47% in 2021, while the deepest fall reached 38.51% in 2021.
  • Tracing JAZZ's Operating Expenses over 5 years: stood at $847.4 million in 2021, then skyrocketed by 45.81% to $1.2 billion in 2022, then dropped by 28.01% to $889.4 million in 2023, then grew by 0.9% to $897.4 million in 2024, then rose by 5.12% to $943.4 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $943.4 million, $1.1 billion, and $1.7 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.